Status and phase
Conditions
Treatments
About
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
• Patients with visual impairment secondary to branch retinal vein occlusion (BRVO) with a BCVA between 19 and 73 letters in one eye and at least 35 letters in the other eye.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
283 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal